Evenity (romosozumab-aqqg) - Astellas, Amgen, UCB
Efficacy of romosuzumab in preventing and treating periprosthetic bone loss after hip replacement (ChiCTR) - Sep 16, 2026 - P=N/A | N=20 | Not yet recruiting | Sponsor: Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University 
New trial • Orthopedics • Osteoporosis
https://www.chictr.org.cn/showproj.html?proj=324769
 
Sep 16, 2026
 
Prev Next